Early IL-6 receptor inhibition with tocilizumab in AMI patients at increased risk of CS safely suppressed systemic inflammation but had an inconclusive effect on NT-proBNP, with a trend toward a favorable effect that did not reach statistical significance. No difference in LV infarct size as assessed with CMR was observed compared with placebo. JACC CRT2026.

The Journal of the American College of Cardiology (JACC) stands as a leading global resource for impactful cardiovascular research, delivering essential peer-reviewed articles and crucial clinical practice guidelines. Gain access to authoritative medical content and vital CME resources designed to advance cardiovascular medicine and improve heart patient outcomes.